Analyst Price Targets — GPCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2026 12:29 pm | Evan Seigerman | BMO Capital | $145.00 | $56.88 | StreetInsider | Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital |
| January 20, 2026 12:20 pm | — | Guggenheim | $140.00 | $88.64 | TheFly | Structure Therapeutics price target raised to $140 from $90 at Guggenheim |
| January 19, 2026 10:26 pm | — | Goldman Sachs | $102.00 | $88.64 | TheFly | Structure Therapeutics moved to Buy rating at Goldman Sachs |
| December 19, 2025 1:43 pm | Ananda Ghosh | H.C. Wainwright | $90.00 | $66.45 | TheFly | Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright |
| December 12, 2025 1:10 pm | Terence Flynn | Morgan Stanley | $125.00 | $66.24 | TheFly | Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley |
| December 11, 2025 2:12 pm | — | Jefferies | $125.00 | $69.64 | TheFly | Structure Therapeutics price target raised to $125 from $79 at Jefferies |
| December 8, 2025 9:03 pm | — | Stifel Nicolaus | $90.00 | $69.98 | TheFly | Structure Therapeutics price target raised to $90 from $50 at Stifel |
| December 2, 2025 2:21 pm | Annabel Samimy | Stifel Nicolaus | $50.00 | $33.89 | StreetInsider | Stifel Reiterates Buy Rating on Structure Therapeutics (GPCR) |
| November 28, 2025 11:35 am | Ananda Ghosh | H.C. Wainwright | $60.00 | $34.22 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR) |
| September 23, 2024 3:15 am | Terence Flynn | Morgan Stanley | $118.00 | $41.92 | StreetInsider | Morgan Stanley Starts Structure Therapeutics (GPCR) at Overweight |
Latest News for GPCR
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can get in on the action by targeting companies that manufacture these powerful drugs.
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of…
Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario.
Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 252,600 shares of the company's stock, valued at approximately $17,568,000. Structure Therapeutics makes
Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, thirteen have
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for GPCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.